Discussion
This is the first time thac C.E.A. or C.E.A.-like material has been demonstrated in the urine ofnormal subjects and ofpatients with urothelial carcinomas. Its presence in urine is not too surprising in view of the common endodermal origin of the urinary bladder and gastrointestinal tract from which latter site and whose tumours C.E.A. was first isolated and thought to be "endodermal specific" (Gold and Freedman, 1965) . Previous studies have shown that C.E.A. occurs in the plasma and faeces of healthy persons (LoGerfo et al., 1971; Moore et al., 1971; Freed and Taylor, 1972; Laurence et al., 1972) and is raised in association with a variety of malignant tumours and disorders associated with regeneration or inflammation or both (LoGerfo et al., 1971 (LoGerfo et al., , 1972 Moore et al., 1971; Laurence et al., 1972; Reynoso et al., 1972; Zamchek et al., 1972) .
From the results of the present series of urinary C.E.A. assays almost 70% (26/38) of subjects with active bladder carcinomas will be found to have raised levels, while normal levels occur in patients who have had successful removal of the tumour (Table I ). In contrast to plasma C.E.A. levels which seem to be raised, particularly after local spread of all types of tumours, high urinary C.E.A. levels occurred in 7 out of 15 examples of Ti bladder carcinomas-that is, showing in-situ or early invasive tumours. Consequently, the assay of urinary C.E.A. appears to be clinically useful in the investigation of patients suspected of having urothelial carcinomas, possibly for the screening of the growing "high-risk" population in certain industries and for the detection of persistent or recurrent carcinoma after appropriate treatment. In this respect, although assay of plasma C.E.A. levels has little to add in the early stages of carcinoma of the bladder, and does not seem to correlate with urinary levels, C.E.A. measurements in plasma and urine are both desirable in the follow-up phases, as plasma values may be raised in the presence of normal urinary levels and so possibly indicate extravesical spread. The J7ournal, 1972, 3, 611-614 Summary Administration of nitrazepam (10 mg nightly), diazepam (15 mg/day), and chlordiazepoxide (15 and 30 mg/day) had no effect on steady-state plasma warfarin concentrations, the plasma half-life of warfarin, or anticoagulant control in patients and it appears safe to prescribe these agents to patients on long-term oral anticoagulants. Urinary excretion of 6 p-hydroxycortisol, however, increased in two out of five patients given chlordiazepoxide. In rats
Introduction
The subject of drug interactions has become very familiar to practising physicians. While a synergistic effect between drugs is widely used in therapeutics more stress is put on the adverse effects of multiple prescribing. This aspect has been widely studied in patients on long-term treatment with oral anticoagulants because such patients are frequently given other agents as part of their treatment and also because both the pharmacological effect and the plasma concentration of the oral anticoagulant can be measured, thus allowing the mechanisms of the interaction to be determined. Pronounced alteration of anticoagulant control in such patients is of obvious clinical importance.
As part of a study to identify hypnotic and sedative drugs which might safely be prescribed to patients on long-term treatment with warfarin we have investigated the effects of administering three benzodiazepines-nitrazepam, diazepam, and chlordiazepoxide-on plasma warfarin concentration and anticoagulant control. The ability of these drugs to alter the rate of drug metabolism in rats has also been investigated since data obtained in animals are frequently extrapolated to man, and the present paper indicates some problems associated with this practice.
Present Series
Patients.-Twelve patients were investigated (10 men and two women aged 32-65 years). Seven were being treated with warfarin because of deep-vein thrombosis, three had rheumatic heart disease with atrial fibrillation, one had a cardiomyopathy, and one had complete heart block with an indwelling pacemaker. Eight of the 12 patients were not on drugs other than warfarin, while four were taking digoxin, two of whom were also taking hydrochlorothiazide. We have previously shown that concurrent administration of digoxin and hydrochlorothiazide to patients taking warfarin has no effect on the plasma warfarin concentration or on anticoagulant control (Breckenridge, Orme, Thorgeirsson, Davies, and Brooks, 1971) . No patient had been on any other drug in the three months before the period of study. Consent was obtained from all patients for these investigations.
Long-term Studies.-Twelve long-term studies were carried out in which the patient's dose of warfarin was kept constant throughout the 100 days of the study. Blood samples were taken twice weekly into plastic syringes in sodium citrate. Anticoagulant control was assessed on the day of sample collection. Plasma was separated and deep frozen for estimation of plasma warfarin concentration. The first 30 to 40 days formed a control period in which good anticoagulant control was achieved and maintained in the therapeutic range (thrombotest 6-10%). Nitrazepam 10 mg nightly (three studies), diazepam 5 mg three times daily (four studies), chlordiazepoxide 5 mg three times daily (three studies), and chlordiazepoxide 10 mg three times daily (two studies) were then given for 30 days. Measurements of anticoagulant control and of plasma warfarin concentration were made during this period and for a further 30 to 40 days after the benzodiazepine had been stopped.
Plasma Half-life of Warfarin.-The plasma half-life of warfarin was measured in three patients before starting benzodiazepine therapy and during the last week of the 30-day benzodiazepine administration. The benzodiazepines studied were diazepam (one patient) and chlordiazepoxide 10 mg three times daily (two patients). Before the initial measurement each patient had been taking warfarin for at least 30 days before it was stopped for a 72-hour period. During this period six blood samples were taken and the plasma half-life of warfarin was calculated by a least squares method with the use of a computer program which gave 95% confidence limits of the half-life measurement. Warfarin was then restarted, anticoagulant control achieved again, and treatment with diazepam or chlordiazepoxide given for 30 days. During the last three days of this treatment warfarin was again stopped for 72 hours and the plasma half-life measured as before.
Urinary 6 3-Hydroxycortisol Excretion.-6 (-Hydroxycortisol is a polar metabolite of cortisol formed in the endoplasmic reticulum of the liver and excreted unconjugated in the urine. It has been suggested that changes in the urine excretion of this steroid can be equated with changes in the activity of the enzymes of hepatic endoplasmic reticulum (Conney, Jacobson, Schneidman, and Kuntzman, 1965 It was significantly shorter in chlordiazepoxide-treated animals (27-5±9-2 min) but not in nitrazepam-treated animals (82-3 ± 13-3 min) or diazepam-treated animals (105-4±27-6 min).
Zoxazolamine Paralysis Time.-The duration of paralysis after zoxazolamine administration in control rats was 262-8± 62-3 min. In chlordiazepoxide-treated rats it was significantly shorter 118-5 ± 13-4 min (P <0-05) but not different from controls in either nitrazepam-treated rats (202-4±79-6 min) or diazepam-treated rats (260-1 ±67-6 min).
Liver Microsomal Enzyme Studies.-The V max of ethylmorphine N-demethylation in control animals was 75-2±4-4 nM/mg protein/10 min. In chlordiazepoxide-treated animal the V max was significantly (P <0-05) greater at 109-3±4-6 nM, but not different from controls in rats treated with nitrazepam (87-1±6-0 nM) or diazepam (80-9±1-9 nM). These studies suggest that in the dose administered chlordiazepoxide stimulates the activity of rat liver microsomal enzymes, but neither nitrazepam nor diazepam have this effect.
PLASMA WARFARIN HALF-LIFE
The plasma warfarin half-life in Case 5 during the control period was 70-5±17 hours and during the administration of diazepam 5 mg three times daily it was 76-9±8-4 hours. In case 9 before chlordiazepoxide 30 mg/day, the plasma warfarin half-life was 29-6±6-4 hours and during this therapy the halflife was 29-9±5-3 hours. Case 10 had a control warfarin half-life of 52-2±8-2 hours, and while receiving chlordiazepoxide 30 mg/day the half-life was 47-2±6-7 hours. In none of these patients, therefore, was there any change in plasma warfarin half-life during the administration of benzodiazepines.
URINARY 6 3-HYDROXYCORTISOL
The administration of diazepam 15 mg/day had no effect on the urinary excretion of 6 P-hydroxycortisol in two patients. The administration of chlordiazepoxide, however, to two out of five patients caused a significant increase in steroid excretion (Table IV) . It was noticeable that there was no change in plasma warfarin concentration or in anticoagulant control in either of these patients when chlordiazepoxide was administered. 
Discussion
These studies form part of a series of investigations in man designed to find hypnotic and sedative drugs which can be given to patients on long-term warfarin therapy without altering anticoagulant control. We have previously shown that dichloralphenazone induces hepatic drug-metabolizing enzyme activity, while chloral hydrate displaces warfarin from binding on plasma albumin through its metabolite trichloroacetic acid . Of barbiturates investigated, both amylobarbitone and quinalbarbitone increased the rate of warfarin metabolism in man . The studies reported here suggest that none of the three benzodiazepines alter either steady-state plasma warfarin concentrations or anticoagulant control. Nitrazepam in a nightly dose of 10 mg can be regarded as one of the safest hypnotics to give patients on warfarin. In rats there was no evidence that pretreatment with large doses of nitrazepam (40 mg/kg/day for four days) altered the activity of drug metabolizing enzymes. Similarly, diazepam altered neither warfarin metabolism in three patients studied nor drug metabolizing activity in rats.
The results with chlordiazepoxide are slightly more difficult to interpret. In doses of 15 mg/day (three patients) or 30 mg/day (two patients) there was no effect on either plasma warfarin concentrations or anticoagulant control. This is in keeping with the findings of Lackner and Hunt (1968) , who found that administration of this agent for 14 days altered neither the anticoagulant response nor the dosage requirements of warfarin. Robinson and Sylvester (1970) showed no effect on the plasma warfarin half-life in eight volunteers given chlordiazepoxide in a mean dose of 50 mg/day for 21 days. Neither was the rate of metabolism of another coumarin anticoagulant increased by chlordiazepoxide administration (van Dam and Overkamp, 1967) . It is thus of some interest to find in two out of five patients that chlordiazepoxide caused an increase in urinary 6 3-hydroxycortisol excretion, which has been advocated as a valuable indication of change in liver microsomal enzyme activity. The enzymes concerned in the formation of this metabolite of cortisol are thought to be those also concerned in drug oxidation (Conney et. al., 1965) .
The cause of this inter-individual difference in cortisol metabolism when chlordiazepoxide is given is not clear. Although benzodiazepines have actions on hypothalamic pathways concerned with the secretion of trophic hormones and with autonomic function (Butler, Besser, and Steinberg, 1968) , it seems most likely that the increase in urinary 6 3-hydroxycortisol output noted here is due to enzyme induction, since the total urine oxogenic steroid output did not increase with chlordiazepoxide administration.
In rats chlordiazepoxide pretreatment (40 mg/kg/day) caused an increase in the activity of the enzymes of drug metabolism. It is appreciated, of course, that this dose is considerably greater than that given in the human studies. This effect in rats has been reported previously (Hoogland, Miya, and Bovsquet, 1966) . It illustrates that great care must be taken in extrapolating the results obtained from animal screening studies of drug metabolism to man.
The importance of these studies is that it appears safe to administer these three benzodiazepines in these doses to patients on long-term warfarin therapy without encountering problems of drug interaction, which are so frequently found with other hypnotics and sedatives. Introduction Barbiturate dependence of varying severity has been known for many years since the account of Clarke (1904) . Physical dependence with major withdrawal symptoms was described experimentally by Isbell (1950) in the U.S.A. and recognized clinically by Wulff (1959) in Denmark. Isbell et al. (1950) and Essig (1967) showed that a daily dose of at least 400 mg of a barbiturate is necessary to produce a clinically significant abstinence syndrome when the drug is withdrawn.
Many patients taking barbiturate and other hypnotics regularly in small dosage never show clinical evidence of physical dependence (Johnson and Clift, 1968) and, as stressed by Tatum and Seevers (1931) , psychological factors are basic in drug dependence. Drug dependence has been described as a desire to take the drug in order to experience its psychic effects (Expert Committee on Drug Dependence, 1969). It has been pointed out (Seevers and Deneau, 1964 ) that a need exists to determine the characteristics of individuals likely to develop drug dependence.
Prescribing patterns of psychotropic drugs in general practice were reviewed by Parish (1971) , who noted the rapid rise in Health and Social Security, 1972) , of which an increasing proportion are for non-barbiturate hypnotics, suggested that a prospective study of patients taking hypnotic drugs might give answers to three questions. (1) Do the non-barbiturate hypnotic drugs as represented by nitrazepam give rise to dependence, and if so is this as likely to occur as with amylobarbitone ?; (2) Are there measurable social, demographic, psychological, or personality-type characteristics which distinguish subjects who develop hypnotic drug dependence from those who do not?; (3) Is nitrazepam as acceptable as amylobarbitone to patients with insomnia ?
Present Study
The patients came from a three-handed general practice in a mainly urban and industrial area of south-east Lancashire. Only patients over the age of 15 years were included from a total list of 7,600, the population at risk being then 5,760.
Two groups of patients were studied; the findings in the first suggesting more detailed examination of the second. Patients were not admitted to either group unless other methods of treating their insomnia had seemed inadequate-for example, analgesics for pain-and the patient still demanded hypnotic drugs.
GROUP 1
Fifty patients presenting consecutively with a recent complaint of insomnia were prescribed a non-barbiturate hypnotic drug by one of the doctors; 43 received nitrazepam, 4 diazepam, and 3 glutethimide. They were not given any special advice about drug dependence and received repeat prescriptions as they felt they required them. Cases were reviewed by me at six months and one year.
